Videos

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are key to closing persistent gaps in preventive care and healthcare access.

Asembia 2025: Designing Smarter Interventions with Community Insights

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and hybrid technology models.

Asembia 2025: How Specialty Pharmacies Are Evolving to Support Rare Conditions

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Articles

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Asembia 2025: Rare Disease Therapies Drive Shift in Drug Development Focus

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

Asembia 2025: How AI and Payer Collaboration Are Shaping Pharmacy's Future

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Asembia 2025: Bridging Health Gaps Through Equity and Education

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.

Asembia 2025: The Role of Face-to-Face Connection in Pharma Commercialization

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. 

Why Distractions Are Detrimental to Business

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

Will Moving Drug Production to the United States Help or Hurt Patients?

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.